Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EMD 273063 antibody, human

Known as: Hu 14.18/IL - 2 Fusion Protein, hu14.18-interleukin-2 fusion protein, EMD 273063 
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity… Expand
National Institutes of Health

Related topics

Related topics

7 relations
Cytotoxic T-LymphocytesReceptor Activation ProcessT-Cell Activationantigen binding
Expand

Broader (2)

Interleukin-2Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response
PurposeImmunotherapy targeting disialoganglioside GD2 emerges as an important treatment option for neuroblastoma, a pediatric… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2011
2011
Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface
The huKS-IL2 immunocytokine (IC) consists of IL2 fused to a mAb against EpCAM, while the hu14.18-IL2 IC recognizes the GD2… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 7
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
Response to immunocytokine (IC) therapy is dependent on natural killer cells in murine neuroblastoma (NBL) models. Furthermore… Expand
Is this relevant?
Review
2009
Review
2009
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
Patients with high risk melanoma and neuroblastoma frequently experience recurrence despite surgical resection and appropriate… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2009
2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
BackgroundTo explore the biological activity of EMD 273063 (hu14.18-IL2), a humanized anti-GD2 monoclonal antibody fused to… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
PURPOSE Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
PURPOSE To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2004
2004
Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Established s.c. NXS2 murine neuroblastoma tumors exhibited transient resolution after suboptimal therapy using the hu14.18-IL2… Expand
Is this relevant?
2003
2003
NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy
We evaluated recurrent NXS2 neuroblastoma tumors that developed following NK- or T-cell–mediated immunotherapy in tumor-bearing… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE